{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:55:39Z","timestamp":1789606539943,"version":"build-2803163510"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme Corp"},{"name":"Merck & Co., Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis) are indicated for treatment of tumors with breast cancer susceptibility genes BRCA1\/2 mutations and homologous recombination deficiency (HRD). Little is known about differences in care by BRCA1\/2 and HRD status for breast and ovarian cancers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We investigated clinical characteristics, treatment, clinical outcomes, and health-care resource utilization by BRCA1\/2 or HRD status among patients diagnosed between 2018-2020 with HER2-negative metastatic breast (mBC) and advanced epithelial ovarian cancer (aEOC) in the United States community healthcare setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 314 patients with mBC and 465 with aEOC. Patients with mBC carrying a BRCA1\/2 mutation were younger and had a higher proportion of triple negative cancer than non-carriers (50% vs 38%). Only 8% of eligible patients received a PARPi in first-line (1L) and 18% in second-line (2L) of treatment for mBC. In aEOC, patients with HRD were younger and a higher proportion received 1L maintenance treatment with a PARPi than patients with non-HRD tumors (95% vs 66%). In aEOC, patients without HRD had greater healthcare resource use. Patients with BRCA-mutated tumors had poorer overall survival (OS); there were no differences in OS by HRD status in aEOC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study demonstrated differences in treatment by BRCA1\/2 and HRD status. There was low PARPi uptake among patients with BRCA-mutated mBC but not among patients with aEOC. In aEOC, the cost to \u201ctreat all\u201d may outweigh benefits; identifying patients without HRD likely to benefit from PARPis is needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf100","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:51:55Z","timestamp":1749196315000},"source":"Crossref","is-referenced-by-count":2,"title":["Treatment, outcomes, and resource utilization among patients with metastatic breast and advanced epithelial ovarian cancer, by BRCA1\/2 and HRD status"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7422-6043","authenticated-orcid":false,"given":"Giovanna I","family":"Cruz","sequence":"first","affiliation":[{"name":"Insights, Syapse Holdings, Inc. , West Chester, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn L","family":"Kane","sequence":"additional","affiliation":[{"name":"Insights, Syapse Holdings, Inc. , West Chester, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayna K","family":"Matsuno","sequence":"additional","affiliation":[{"name":"Insights, Syapse Holdings, Inc. , West Chester, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Sweetnam","sequence":"additional","affiliation":[{"name":"Insights, Syapse Holdings, Inc. , West Chester, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne F O","family":"Williams","sequence":"additional","affiliation":[{"name":"Insights, Syapse Holdings, Inc. , West Chester, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz M","family":"Toland","sequence":"additional","affiliation":[{"name":"Insights, Syapse Holdings, Inc. , West Chester, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Stone","sequence":"additional","affiliation":[{"name":"Insights, Syapse Holdings, Inc. , West Chester, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna B","family":"Berry","sequence":"additional","affiliation":[{"name":"Insights, Syapse Holdings, Inc. , West Chester, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika A","family":"Izano","sequence":"additional","affiliation":[{"name":"Insights, Syapse Holdings, Inc. , West Chester, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam C","family":"Lee","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagadeswara R","family":"Earla","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D","family":"Brown","sequence":"additional","affiliation":[{"name":"Insights, Syapse Holdings, Inc. , West Chester, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W","family":"Drescher","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute , Seattle, WA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry G","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute , Seattle, WA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Kothari","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Sillah","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gieira","family":"Jones","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. , Rahway, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"2025081219184888300_CIT0001","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br J Cancer"},{"key":"2025081219184888300_CIT0002","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"key":"2025081219184888300_CIT0003","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"2025081219184888300_CIT0004","doi-asserted-by":"publisher","first-page":"e4975","DOI":"10.1097\/MD.0000000000004975","article-title":"Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis","volume":"95","author":"Baretta","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"2025081219184888300_CIT0005","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10549-021-06104-y","article-title":"Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis","volume":"186","author":"Liu","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2025081219184888300_CIT0006","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA -positive and BRCA -negative breast cancer","volume":"26","author":"Atchley","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025081219184888300_CIT0007","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1159\/000523970","article-title":"Treatment patterns, safety, and patient reported outcomes among adult women with human epidermal growth factor receptor 2-negative advanced breast cancer with or without, or with unknown, BRCA1\/2 Mutation(s): results of a real-world Study from the United States, United Kingdom, and four EU Countries","volume":"17","author":"Lux","year":"2022","journal-title":"Breast Care (Basel, Switzerland)"},{"key":"2025081219184888300_CIT0008","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1186\/s12885-019-6277-x","article-title":"Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain)","volume":"19","author":"Ruiz De Sabando","year":"2019","journal-title":"BMC Cancer"},{"key":"2025081219184888300_CIT0009","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13058-020-01349-9","article-title":"Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study","volume":"22","author":"O\u2019Shaughnessy","year":"2020","journal-title":"Breast Cancer Res: BCR"},{"key":"2025081219184888300_CIT0010","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.17.00286","article-title":"Prevalence of homologous recombination\u2013related gene mutations across multiple cancer types","volume":"2","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2025081219184888300_CIT0011","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10549-022-06541-3","article-title":"Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ\u00ae study","volume":"193","author":"Miller","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2025081219184888300_CIT0012","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"2025081219184888300_CIT0013","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13048-019-0511-7","article-title":"Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer","volume":"12","author":"Kim","year":"2019","journal-title":"J Ovarian Res"},{"key":"2025081219184888300_CIT0014","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"2025081219184888300_CIT0015","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1158\/1078-0432.CCR-17-1621","article-title":"Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer","volume":"24","author":"Garsed","year":"2018","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"2025081219184888300_CIT0016","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1158\/1078-0432.CCR-14-2497","article-title":"Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer","volume":"21","author":"Candido-dos-Reis","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2025081219184888300_CIT0017","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/jnci\/djs494","article-title":"Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2","volume":"105","author":"McLaughlin","year":"2013","journal-title":"JNCI J Natl Cancer Inst."},{"key":"2025081219184888300_CIT0018","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2015.11.009","article-title":"Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status","volume":"140","author":"Kotsopoulos","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2025081219184888300_CIT0019","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3390\/cancers13050946","article-title":"Modification of homologous recombination deficiency score threshold and association with long-term survival in epithelial ovarian cancer","volume":"13","author":"How","year":"2021","journal-title":"Cancers"},{"key":"2025081219184888300_CIT0020","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/s0090-8258(22)01414-7","article-title":"Correlation of BRCA and HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer in the age of PARPi maintenance therapy (187)","volume":"166","author":"Sims","year":"2022","journal-title":"Gynecol Oncol"},{"key":"2025081219184888300_CIT0021","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"2025081219184888300_CIT0022","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"2025081219184888300_CIT0023","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","article-title":"OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"184","author":"Robson","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025081219184888300_CIT0024","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"2025081219184888300_CIT0025","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"2025081219184888300_CIT0026","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"2025081219184888300_CIT0027","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025081219184888300_CIT0028","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1\/GOG 3004 Trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025081219184888300_CIT0029","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"2025081219184888300_CIT0030","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025081219184888300_CIT0031","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"2025081219184888300_CIT0032","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet (London, England)"},{"key":"2025081219184888300_CIT0033","doi-asserted-by":"publisher","first-page":"e2400079","DOI":"10.1200\/OA-24-00079","article-title":"Patterns of homologous repair deficiency and BRCA1\/2 testing of ovarian and breast cancers: a real-world study of patients in community health settings in the United States","volume":"2","author":"Matsuno","year":"2025","journal-title":"JCO Oncol Adv"},{"key":"2025081219184888300_CIT0034","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2025081219184888300_CIT0035","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative Data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"2025081219184888300_CIT0036","doi-asserted-by":"publisher","first-page":"A056","DOI":"10.1158\/1538-7445.ovarian23-a056","article-title":"Abstract A056: development and application of an epithelial ovarian cancer-specific line of therapy algorithm using real-world data","volume":"84","author":"Sweetnam","year":"2024","journal-title":"Cancer Res"},{"key":"2025081219184888300_CIT0037","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1200\/CCI.20.00143","article-title":"Validation of a mortality composite score in the real-world setting: overcoming source-specific disparities and biases","volume":"5","author":"Lerman","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"2025081219184888300_CIT0038","author":"RStudio Team","year":"2020"},{"key":"2025081219184888300_CIT0039","volume-title":"FDA approves olaparib for germline BRCA-mutated metastatic breast cancer","author":"Research C for DE and","year":"9, 2019"},{"key":"2025081219184888300_CIT0040","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.breast.2022.10.009","article-title":"Real-world study of patients with germline BRCA1\/2-mutated human epidermal growth factor receptor 2\u2013Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel","volume":"66","author":"Mahtani","year":"2022","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"2025081219184888300_CIT0041","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1186\/s12913-021-07196-4","article-title":"Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review","volume":"21","author":"Medlinskiene","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"2025081219184888300_CIT0042","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ijc.34304","article-title":"Survival outcomes of metastatic breast cancer patients by germline BRCA1\/2 status in a large multicenter real-world database","volume":"152","author":"Mailliez","year":"2023","journal-title":"Int J Cancer"},{"key":"2025081219184888300_CIT0043","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3892\/ol.2013.1684","article-title":"Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer","volume":"7","author":"Maksimenko","year":"2014","journal-title":"Oncol Lett"},{"key":"2025081219184888300_CIT0044","doi-asserted-by":"publisher","first-page":"7073","DOI":"10.1038\/s41598-020-63759-1","article-title":"Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes","volume":"10","author":"De Talhouet","year":"2020","journal-title":"Sci Rep"},{"key":"2025081219184888300_CIT0045","doi-asserted-by":"publisher","first-page":"100121","DOI":"10.1016\/j.ctarc.2019.100121","article-title":"Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings","volume":"19","author":"Houts","year":"2019","journal-title":"Cancer Treat Res Commun"},{"key":"2025081219184888300_CIT0046","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s12325-018-0867-x","article-title":"Clinical outcomes, treatment patterns, and health resource utilization among metastatic breast cancer patients with germline BRCA1\/2 mutation: A Real-World Retrospective Study","volume":"36","author":"Quek","year":"2019","journal-title":"Adv Ther"},{"key":"2025081219184888300_CIT0047","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A Randomized, Phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA\u2013MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025081219184888300_CIT0048","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/AOG.0000000000003171","article-title":"Food and drug administration\u2013approved poly (ADP-Ribose) polymerase inhibitor maintenance therapy for recurrent ovarian cancer: a cost-effectiveness analysis","volume":"133","author":"Dottino","year":"2019","journal-title":"Obstet Gynecol"},{"key":"2025081219184888300_CIT0049","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ygyno.2020.08.003","article-title":"Cost-effectiveness analysis comparing \u201cPARP inhibitors-for-all\u201d to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer","volume":"159","author":"Gonzalez","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2025081219184888300_CIT0050","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","article-title":"Estimation of the number of women living with metastatic breast cancer in the United States","volume":"26","author":"Mariotto","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyaf100\/64008838\/oyaf100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyaf100\/64008838\/oyaf100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T23:18:54Z","timestamp":1755040734000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf100\/8230714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf100","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,8]]},"article-number":"oyaf100"}}